ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03478280
Recruitment Status : Not yet recruiting
First Posted : March 27, 2018
Last Update Posted : March 27, 2018
Sponsor:
Collaborator:
LEO Pharma
Information provided by (Responsible Party):
Anne Bregnhøj, Aarhus University Hospital

Brief Summary:
A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Brodalumab Drug: Placebos Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A randomised, double-blind, placebo-controlled, trial
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
Estimated Study Start Date : April 15, 2018
Estimated Primary Completion Date : March 15, 2020
Estimated Study Completion Date : March 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Brodalumab

Arm Intervention/treatment
Active Comparator: Brodalumab
Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
Drug: Brodalumab
Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Other Name: Kyntheum

Placebo Comparator: Placebo
Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
Drug: Placebos
Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period




Primary Outcome Measures :
  1. The aortic wall inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo. [ Time Frame: 16 weeks ]
    The average of maximum TBR values (MeanTBRmax) of the entire aorta at baseline and at week 16


Secondary Outcome Measures :
  1. The splenic inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo. [ Time Frame: 16 weeks ]
    The spleen-to-liver ratio (SLR) based on splenic and liver mean standardised uptake values (SUVmean)

  2. The aortic wall subsegment inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo. [ Time Frame: 16 weeks ]
    The average of maximum TBR values (MeanTBRmax) of the ascending, aortic arch, descending, suprarenal, and infrarenal aorta at baseline and at week 16

  3. The skin inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo. [ Time Frame: 16 weeks ]
    Severity of psoriasis measured by PASI score at baseline and at week 16



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent obtained from the subject prior to performing any protocol-related procedures.
  2. Age 40 and above.
  3. Diagnosis of chronic plaque psoriasis confirmed by a dermatologist
  4. PASI ≥ 10

Exclusion Criteria:

  1. Non-Danish speaking
  2. Known or suspected allergy or reaction to any component of the IMP formulation.
  3. History of inflammatory bowel disease, arthritis (not including psoriatic arthritis), systemic lupus erythematosus, and active inflammatory skin diseases.
  4. A history of malignancies within the past five years (excluding localized non-melanoma skin cancer).
  5. Topical corticosteroid treatment (class III or stronger) and/or ultraviolet type B phototherapy within 2 weeks prior to randomization
  6. Treatment with psoralen plus ultraviolet type A photochemotherapy, methotrexate, cyclosporine, acitretin, or fumaric acid esters within 4 weeks prior to randomization.
  7. Treatment with adalimumab, etanercept, infliximab, cosentyx, or ixekizumab within 12 weeks, ustekinumab within 24 weeks, or other immunosuppressive or anti-inflammatory agents within 5 half-lives of the active substance prior to the FDG-PET/CT, respectively.
  8. Scheduled surgery during the trial period (expect minor minimally invasive procedures).
  9. Systemic infection or fever within 7 days prior to FDG-PET/CT.
  10. Severe obesity (> 150 kg due to a PET/CT scanner limitation).
  11. Presence of uncontrolled diabetes mellitus (HbA1c > 75 mmol/mol and/or blood sugar > 11.1 mmol/l and/or clinical judgment).
  12. History of coagulation defects (clinical judgment).
  13. Active or latent tuberculosis requiring treatment.
  14. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.
  15. History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications as determined by medical history and/or subject's verbal report.
  16. No history of varicella zoster infection and negative varicella antibody test (until varicella vaccination is completed).
  17. History of chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance as judged by the investigator.
  18. History of intravenous drug use.
  19. History of attempted suicide or is at significant risk of suicide.
  20. Major surgery within the past 3 months.
  21. Pregnancy or lactation (Women of childbearing potential must use a highly effective* form of birth control (confirmed by the investigator) throughout the trial and until 12 weeks after discontinuation of treatment with brodalumab.
  22. Claustrophobia.
  23. Reduced renal function (serum creatinine > 200 μmol/L or cr-EDTA clearance < 30 ml/min)
  24. Any disorder, including but not limited to, cardiovascular, lung, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, psychiatric, or major physical impairment that is not stable, in the opinion of the investigator, and could:

    • Affect the safety of the subject throughout the trial.
    • Influence the findings of the trial or their interpretations.
    • Impede the subject's ability to complete the entire duration of trial.

      • A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), sexual abstinence (when this is in line with the preferred and usual life style of the subject), vasectomised partner (given that the subject is monogamous). The subjects must have used the contraceptive method continuously for at least 1 month prior to the pregnancy test. A female is defined as not being of child bearing potential if she is postmenopausal (at least 12 months with no menses without an alternative medical cause prior to screening), or surgically sterile (hysterectomy, bilateral salpingectomy or bilateral oophorectomy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03478280


Contacts
Contact: Anne Bregnhøj, MD, PhD +45 2183 5720 annebreg@rm.dk

Sponsors and Collaborators
Aarhus University Hospital
LEO Pharma
  Study Documents (Full-Text)

Documents provided by Anne Bregnhøj, Aarhus University Hospital:
Study Protocol and Informed Consent Form  [PDF] February 23, 2018


Responsible Party: Anne Bregnhøj, MD, PhD, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT03478280     History of Changes
Other Study ID Numbers: PsoPET2
First Posted: March 27, 2018    Key Record Dates
Last Update Posted: March 27, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Inflammation
Psoriasis
Pathologic Processes
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs